English
中文
Top search
Atopic dermatitis Chronic prurigo Epidermolysis bullosa Psoriasis Immune-mediated kidney disease Glaucoma
News
Company News Industry trends
PG-011 IIb Clinical Data Blinded Successfully Meets Both Primary and Secondary Endpoints SPA | Spotlight
2023-12-05
PG-011 IIb Clinical Data Blinded Successfully Meets Both Primary and Secondary Endpoints SPA | Spotlight
Subject Recruitment of PG-011 Gel for the Treatment of Recurrent, Itchy Skin in Adolescents with Mild to Moderate Atopic Dermatitis
2023-08-15
Subject Recruitment of PG-011 Gel for the Treatment of Recurrent, Itchy Skin in Adolescents with Mild to Moderate Atopic Dermatitis
PrimegeGene's PG-011 Gel Makes Positive Progress in Exploratory Clinical Study for the Treatment of Nodular Itchy Rash
2023-09-15
PrimegeGene's PG-011 Gel Makes Positive Progress in Exploratory Clinical Study for the Treatment of Nodular Itchy Rash
PG-011 IIb Clinical Data Blinded Successfully Meets Both Primary and Secondary Endpoints SPA | Spotlight
2023-12-05
PG-011 IIb Clinical Data Blinded Successfully Meets Both Primary and Secondary Endpoints SPA | Spotlight
Subject Recruitment of PG-011 Gel for the Treatment of Recurrent, Itchy Skin in Adolescents with Mild to Moderate Atopic Dermatitis
2023-08-15
Subject Recruitment of PG-011 Gel for the Treatment of Recurrent, Itchy Skin in Adolescents with Mild to Moderate Atopic Dermatitis
PrimegeGene's PG-011 Gel Makes Positive Progress in Exploratory Clinical Study for the Treatment of Nodular Itchy Rash
2023-09-15
PrimegeGene's PG-011 Gel Makes Positive Progress in Exploratory Clinical Study for the Treatment of Nodular Itchy Rash
Mr. Ye Dong joined PrimeGene as production quality vice president
2022-08-23
Mr. Ye Dong joined PrimeGene as production quality vice president
PrimegeGene wins two more invention patent certificates and steadily strengthens its innovation strength.
2022-11-22
PrimegeGene wins two more invention patent certificates and steadily strengthens its innovation strength.
PrimeGene completed A+ round financing of over RMB100 million, and StartPointAdvisers started to act as its exclusive financial advisor
2022-12-02
PrimeGene completed A+ round financing of over RMB100 million, and StartPointAdvisers started to act as its exclusive financial advisor
Dr. Du Yunlong (CEO of PrimeGene): Focus on research and development of new-generation innovative external drugs pertaining to immune adjustment and inflammatory targets
2023-03-13
Dr. Du Yunlong (CEO of PrimeGene): Focus on research and development of new-generation innovative external drugs pertaining to immune adjustment and inflammatory targets
About us
Approaching PrimeGene Coporate culture Development course Top management Honors & qualifications
Scientific research
Scientific and technological innovation Therapeutic area Product lines Win-win cooperation
News
Company News Industry trends
Recruitment
Philosophy on personnel Job duties
Get in touch with us
Floor 5&6, Tower B, Chongxin Building, Hangfeng Road 13#, Fengtai District, Beijing
010-83141848
Copyright owner：Prime Gene Therapeutics Co.,Ltd.
Copyright © 2023 All Rights Reserved.京ICP备2022001152号-1
Contact us Sitemap Privacy policy Legal statement